Safety and Efficacy of Atogepant for Migraine Prevention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract
Migraine represents a widespread neurological disorder that causes substantial disability and impacts on quality of life and functioning. An oral calcitonin gene-related peptide (CGRP) receptor antagonist, atogepant, is a new targeted preventive treatment for migraine. This systematic review and meta-analysis aimed to evaluate the effectiveness and safety profile of atogepant in migraine prevention. According to the PRISMA guidelines, relevant studies were identified through a thorough database search in the PubMed, Cochrane, and ScienceDirect databases to identify all randomized controlled trials (RCTs) evaluating atogepant in adults with episodic or chronic migraine. A total of six high-quality RCTs and 3,453 patients were included. The outcomes evaluated were monthly migraine days (MMDs), monthly headache days (MHDs), acute migraine medication use, and adverse events. Pooled analysis demonstrated that atogepant significantly reduced MMDs (mean difference (MD) = -1.47; 95% CI -1.73 to -1.21), MHDs (MD = -1.71; 95% CI -1.95 to -1.48), and acute migraine medication use (MD = -1.69; 95% CI -1.94 to -1.44) compared with placebo across dose levels. Higher doses with reductions were observed, particularly with the 60 mg once-daily and 30 mg twice-daily doses. Atogepant was effective in hard-to-treat populations such as those with chronic migraine and headaches related to medication overuse. The overall risk of adverse events was slightly higher with atogepant than with placebo…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 3,453 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.